Akari Therapeutics (AKTX) Getting Somewhat Favorable News Coverage, Accern Reports

Press coverage about Akari Therapeutics (NASDAQ:AKTX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akari Therapeutics earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.0504644359164 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the headlines that may have effected Accern’s scoring:

Shares of Akari Therapeutics (AKTX) traded down $0.06 on Tuesday, hitting $2.12. 137,751 shares of the stock were exchanged, compared to its average volume of 179,621. The stock has a market capitalization of $25.08, a price-to-earnings ratio of -7.57 and a beta of -8.01. Akari Therapeutics has a 1 year low of $1.79 and a 1 year high of $22.20.

AKTX has been the subject of a number of recent analyst reports. ValuEngine raised shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. Zacks Investment Research lowered shares of Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Finally, B. Riley initiated coverage on shares of Akari Therapeutics in a research note on Thursday, February 8th. They set a “neutral” rating and a $3.00 target price for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $6.38.

ILLEGAL ACTIVITY WARNING: This piece was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://stocknewstimes.com/2018/03/20/akari-therapeutics-aktx-getting-somewhat-favorable-news-coverage-accern-reports.html.

About Akari Therapeutics

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Insider Buying and Selling by Quarter for Akari Therapeutics (NASDAQ:AKTX)

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply